MRK241213C85000
- 14.95
- 0.000.00%
Merck & Co Newsroom
Weekly Buzz: Tech stocks hit high scores on ominous day
Bicycle Therapeutics Reports Updates Across Zelenectide Pevedotin Program; Shares Slump
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Market Mixed on Friday the 13th | Livestock
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Merck & Co. Gets Key European Backing for Welireg in Two Uses
Express News | Merck: Final Decision Is Expected in Q1 of 2025
Express News | Merck Receives Positive EU Chmp Opinion for Welireg® (Belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
Express News | EMA's Chmp: Recommended Granting Conditional Marketing Authorisation for Welireg (Belzutifan)
Merck & Co To Go Ex-Dividend On December 16th, 2024 With 0.81 USD Dividend Per Share
Merck (MRK) Ascends While Market Falls: Some Facts to Note
Thursday Ends in Index Declines | Wall Street Today
"Person of the Year" Trump rings the opening bell at the NYSE, emphasizing that "the stock market is everything."
On December 12, the elected President Trump was named Time Magazine's Person of the Year for 2024, ringing the opening bell at the NYSE that day; Trump rang the bell with the CEO of ICE and the CEO of Time Magazine, along with the president of the NYSE, while the CEOs of companies such as Goldman Sachs and Citigroup were present; Trump promised an "unprecedented economy," planned to increase oil drilling to reduce inflation, and committed to lowering the corporate tax rate to 15%.
Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock
Daily short sale tracking: Itau Unibanco's short volume increased by 7 million, with a short sale ratio of 16%
CITIC Securities: Maintain the "Outperform Industry" rating for He Yu-B with a Target Price of HKD 6.76.
CICC released a research report stating that it maintains the forecast for Haoyu-B (02256) parent Net income for 2024 and 2025 at 2.13 million RMB and 2.7 million RMB unchanged. According to the DCF model, the bank maintains an outperform rating for the Industry and a Target Price of 6.76 HKD. On December 8, the company announced that it reported the preliminary phase II study results of Pimicotinib (ABSK021) for the treatment of 2L+ chronic graft-versus-host disease (cGvHD) at the 66th American Society of Hematology (ASH) annual meeting. Although most enrolled patients have not completed cGvHD relief.
Trump is reportedly set to ring the bell at the NYSE today. What does it signify?
① According to media reports, the USA's incoming president Trump will go to the NYSE on Thursday to ring the opening bell and deliver a speech; ② There are reports that Trump will be named Time Magazine's Person of the Year for 2024, but this has not yet been confirmed by Time; ③ Since Trump's announcement of victory, the three major US stock indices have risen repeatedly, with the market encouraged by promises of tax cuts and deregulation.
AstraZeneca (AZN.US) and MSD (MRK.US) announce long-term results from phase 3 Olympia clinical trial
Lynparza is a “first-in-class” PARP inhibitor and the first synthetic lethal targeted therapy to target cells/tumors with homologous recombinant repair (HRR) defects (such as cells carrying BRCA1 and/or BRCA2 mutations).
AstraZeneca, Merck's Lynparza Shows Prolonged Survival Benefit in Early Breast Cancer Patients
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock